Written Authority Required Drugs 012-63060000
This document outlines information and phone enquiry details for each Written Authority Required medicine.
Written authority approval required
Some medicines used to treat chronic conditions require written authority approval from Services Australia before they can be subsidised under the Pharmaceutical Benefits Scheme (PBS).
Due to the clinical use or other special features of these medicines, applications for authority approval must be made in writing.
The medicine is not PBS-subsidised without authority approval, and retrospective approval (often known as an 'owing' script) is not allowable under the PBS.
Complex Drugs Programs portal
A team portal is available to agency staff trained in delivering Pharmaceutical Benefits Scheme (PBS) Complex Drugs program services.
The portal provides easy access to commonly used sources including databases and letters.
To access the portal, go to the specialised drugs drive, open the 'portal folder' and select 'portal start up'.
Clean-up reports
Clean up reports are required to be actioned before the end of each calendar month for accuracy in statistical reporting. See the Process page for how to run a clean-up report.
The Resources page contains links to contact details and the Services Australia website, and information on each written authority required drug administered by Services Australia.
Contents
Acromegaly Program in Pharmaceutical Benefits Scheme (PBS)
Acute lymphoblastic leukaemia (ALL) Program in Pharmaceutical Benefits Scheme (PBS)
Acute myeloid leukaemia (AML) Program in Pharmaceutical Benefits Scheme (PBS)
Ankylosing spondylitis (AS) Program in Pharmaceutical Benefits Scheme (PBS)
Atypical haemolytic uraemic syndrome (aHUS) Program in Pharmaceutical Benefits Scheme (PBS)
Basal cell carcinoma Program in Pharmaceutical Benefits Scheme (PBS)
Breast Cancer Programs in Pharmaceutical Benefits Scheme (PBS)
Cardiomyopathy (CM) Program in Pharmaceutical Benefits Scheme (PBS)
Chronic kidney disease-associated pruritus (CKD-aP) Program in Pharmaceutical Benefits Scheme (PBS)
Chronic myeloid leukaemia (CML) Program in Pharmaceutical Benefits Scheme (PBS)
Chronic myelomonocytic leukaemia Program in Pharmaceutical Benefits Scheme (PBS)
Chronic rhinosinusitis with nasal polyps (CRSwNP) in Pharmaceutical Benefits Scheme (PBS)
Chronic spontaneous urticaria (CSU) Program in Pharmaceutical Benefits Scheme (PBS)
Crohn's disease (CD) Program in Pharmaceutical Benefits Scheme (PBS)
Cystic fibrosis (CF) Program in Pharmaceutical Benefits Scheme (PBS)
Eye (CNV DMO RVO) Programs in Pharmaceutical Benefits Scheme (PBS)
Fabry disease (FD) Program in Pharmaceutical Benefits Scheme (PBS)
Gastric cancer (GC) Programs in Pharmaceutical Benefits Scheme (PBS)
Gastrointestinal stromal tumour Program in Pharmaceutical Benefits Scheme (PBS)
Giant cell arteritis (GCA) Program in Pharmaceutical Benefits Scheme (PBS)
Growth hormone deficiency - paediatric patients Program in Pharmaceutical Benefits Scheme (PBS)
Hereditary angioedema (HAE) type 1 or 2 Program in Pharmaceutical Benefits Scheme (PBS)
Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS)
Hidradenitis suppurativa (HS) Program in Pharmaceutical Benefits Scheme (PBS)
Hodgkin lymphoma (HL) Program in Pharmaceutical Benefits Scheme (PBS)
Idiopathic pulmonary fibrosis (IPF) Program in Pharmaceutical Benefits Scheme (PBS)
Idiopathic thrombocytopenic purpura (ITP) Program in Pharmaceutical Benefits Scheme (PBS)
Juvenile arthropathies (JIA and sJIA) Program in Pharmaceutical Benefits Scheme (PBS)
Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS)
Myelodysplastic syndrome Program in Pharmaceutical Benefits Scheme (PBS)
Myelofibrosis Program in Pharmaceutical Benefits Scheme (PBS)
Narcolepsy Program in Pharmaceutical Benefits Scheme (PBS)
Neurofibromatosis type 1 (NF1) Program in Pharmaceutical Benefits Scheme (PBS)
Non-infectious uveitis (NIU) Program in Pharmaceutical Benefits Scheme (PBS)
Non-radiographic axial spondyloarthritis (AXSPA) Program in Pharmaceutical Benefits Scheme (PBS)
Non-small cell lung cancer (NSCLC) Program in Pharmaceutical Benefits Scheme (PBS)
Paroxysmal nocturnal haemoglobinuria (PNH) Program in Pharmaceutical Benefits Scheme (PBS)
Psoriasis (PSOR) Program in Pharmaceutical Benefits Scheme (PBS)
Psoriatic arthritis (PSA) Program in Pharmaceutical Benefits Scheme (PBS)
Pulmonary arterial hypertension (PAH) Program in Pharmaceutical Benefits Scheme (PBS)
Rheumatoid arthritis (RA) Program in Pharmaceutical Benefits Scheme (PBS)
Severe aplastic anaemia Program in Pharmaceutical Benefits Scheme (PBS)
Severe asthma (SA) Program in Pharmaceutical Benefits Scheme (PBS)
Severe facial lipoatrophy Program in Pharmaceutical Benefits Scheme (PBS)
Short bowel syndrome (SBS) Program with intestinal failure in Pharmaceutical Benefits Scheme (PBS)
Solid tumours with confirmed NTRK gene fusion Program in Pharmaceutical Benefits Scheme (PBS)
Spinal muscular atrophy (SMA) Program in Pharmaceutical Benefits Scheme (PBS)
Systemic light chain amyloidosis (AL) Program in Pharmaceutical Benefits Scheme (PBS)
Systemic lupus erythematosus (SLE) Program in Pharmaceutical Benefits Scheme (PBS)
T-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS)
Ulcerative colitis (UC) Program in Pharmaceutical Benefits Scheme (PBS)
X-linked hypophosphataemia (XLH) Program in Pharmaceutical Benefits Scheme (PBS)
Complex drugs prescriber database
Processing Complex Authority Required Listings
Related links
Pharmaceutical Benefits Scheme (PBS) - Authority required and Section 100 - Health Professionals